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Abstract 
Introduction: Research suggests that chemotherapy may be related to decline in 
patients’ cognitive functions.  
Objectives: To assess the feasibility and acceptability of a multi-site study designed 
to examine the nature and extent of chemotherapy-related cognitive changes in 
colorectal cancer patients.   
Method: Data was collected over 8 months using objective and self-reported 
measures of cognitive functioning and self-reported quality of life, fatigue and mood 
questionnaires. The assessment battery was administered pre- and mid-
chemotherapy treatment to a consecutive sample of colorectal cancer patients 
across three London-based NHS Trusts. Participants included patients who had 
undergone colorectal surgery and were scheduled to have adjuvant chemotherapy 
treatment, or no further cancer treatment.   
Main outcome measures: Recruitment procedures, rate of recruitment, suitability of 
exclusion/inclusion criteria, acceptability of data collection procedures and the 
battery, and attrition rates. 
Results:  From 1 April 2014 to 1 December 2014, 42 eligible participants were invited 
to take part in the trial. Of the 17 that completed pre-chemotherapy assessments, 
only 1 withdrew at follow-up due to reasons of ill health from disease recurrence.  All 
participants completed the entire battery and indicated that they found the trial 
acceptable. 
Conclusions:   
What went wrong: Strained researcher resources; loss of eligible participants to 
competing studies, restrictive upper age limit.   
Possible solutions:  Removal of upper age limit, an increased dedicated research 
team to increase rate of recruitment. 
The Protocol is feasible with suggested amendments and is acceptable to patients 
and medical teams. Acceptability of trial to medical teams is further evidenced by 
requests of collaboration from two additional London based NHS Trusts.  
Lessons learned: This feasibility trial provides evidence to other researchers 
designing similar studies in this area of an acceptable design and the need for 
appropriate funding for resources to recruit a large enough consecutive sample of 
solid tumour cancer patients.  
 
 
1. Introduction 
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Research suggests that chemotherapy may be related to a decline in cognitive 
functions such as memory and attention in some solid tumour cancer patients 
(Collins, Mackenzie, Stewart, Bielajew, and Verma, 2009; Myers, 2009; Weis, 
Poppelreuter and Bartsch, 2009; Wefel, Lenzi, Theriault, Davis and Meyers, 2004). 
However, the presence, extent and course of any cognitive decline and whether or 
not it causes observable difficulties for patients remain unclear.  
 
The majority of research studies to date have explored cognitive function in cancer 
patients after treatment has been completed (Vardy, Wefel, Ahles, Tannock and 
Schagen, 2008). Few studies have measured patients’ cognitive function prior to the 
commencement of chemotherapy treatment and hence these studies do not have 
any baseline. Measuring cognitive function both before and after chemotherapy 
would make it possible to identify changes occurring during treatment and the 
duration of such treatment induced changes.  
 
An additional limitation of existing studies is that they have often lacked a 
comparison group (e.g. cancer patients who have not required chemotherapy) 
against which to compare cognitive function scores. Furthermore, the majority of 
cognitive research to date has focussed on female breast cancer patients. This has 
precluded an exploration of gender differences in relation to cognitive decline. 
 
This study examines the feasibility of a protocol designed to examine the nature and 
extent of chemotherapy related cognitive changes in colorectal cancer (“CRC”) 
patients (the “Protocol”)(Dwek, Rixon, Simon, Hurt and Newman, 2015).  Given the 
proposed scale of the study, it was considered appropriate to first conduct a 
feasibility trial (the “Trial”). It is good practice and important for research to carry out 
this type of feasibility trial prior to a full study (Arain, Campbell, Cooper, and 
Lancaster, 2010). The Trial would determine the resources required, whether the 
Protocol could be implemented as designed, or whether any alterations were 
necessary.  
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2. Objectives 
 
Bowen et al (2009) suggested eight general areas of focus that may be addressed 
by feasibility studies for proposed interventions. This was narrowed to four areas, as 
the Trial did not involve an intervention. (See Table 1, which defines how the areas 
of focus correspond to the Trial objectives).   
 
Table 1: Areas of Focus and Trial Objectives  
Areas of Focus Trial Objectives  
Implementation (the extent to 
which and the likelihood that 
the proposed multi-site study 
can be fully implemented in 
accordance with the Protocol1) 
To what extent can the recruitment procedures be 
carried out as proposed? How willing are the 
clinical teams to facilitate and/or help recruit 
participants?  
Practicality (an exploration of 
the extent to which the 
Protocol may be delivered 
given available resources and 
time1)  
Capacity of staff and logistics.  
Acceptability (how will the 
individual recipients (both 
patients and clinicians) react 
to the procedures and 
assessments1)  
Acceptability of the data collection procedures and 
assessments to participants and clinicians?  
Practicality Attrition rates and time needed to collect and 
analyse data  
1These are an adaptation of the definitions of each area of focus provided by Bowen et al, 2009  
 
2.1 The primary objectives of this Trial were to evaluate:  
 
2.1.1. Recruitment procedures 
In order to assess the maximum number of eligible participants, the most efficient 
procedures for recruitment were examined in order to establish and confirm the:  
a) Extent to which the suggested recruitment procedures could be carried out as 
proposed 
b) Similarities/differences in recruitment procedures between the three collaborating 
London based NHS Trusts (the ‘Trusts’) 
c) Extent to which the clinical teams were supportive of the Trial 
d) Ease of identifying eligible participants  
e) Number of eligible participants per Trust. 
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2.1.2 Participant numbers 
A critical issue was to examine the patient flow as determined by the consent rate of 
eligible participants entering this Trial (Ross-McGill, Hewison, Hirst, Dowswell, Holt, 
Brunskill, & Thornton, 2000; Burrows, Gan, Gallus, Wallace, & Burrows, 2001; 
Carfoot, Dickson, Williamson, 2002) in order to:  
 
a) Determine the time necessary to recruit a sufficient sample 
b) Make projections of the funding and resources needed to execute an 
appropriately powered multi-site study 
c) Assess the suitability of inclusion/exclusion criteria. 
 
2.1.3 Methodology/testing of data collection procedures and assessments 
The piloting and assessing acceptability of the proposed technique of data collection 
(Carfoot, Dickson, Williamson, 2002) according to the Protocol, was important, as 
each participant was required undergo a series of neuropsychological assessments 
and questionnaires (the “Battery”).  
 
2.1.4 Attrition rates 
Similar research in breast cancer treatment suggests that attrition rates in 
longitudinal cohort studies range from 10% to 33% (Hurria, Rosen, Hudis, 
Zuckerman, et al, 2006; Reid-Arndt, Hsieh, Perry, 2010; Vearncombe, Rolfe, Wright, 
Pachana, Andrew, Beadle, 2009; Wefel, Saleeba, Buzdar, Meyers, 2010). The 
extent to which these data would be generalisable to the proposed population who 
differed in age, gender, cancer type and course of treatment needed to be 
determined.  
 
Ethical Approval 
 
Ethical approval was obtained from the NHS Health Research Authority – NRES 
Committee South-West Cornwall & Plymouth in August 2013. As part of the approval 
process it was also necessary to obtain a patient’s perspective and view of the 
proposed Trial. Therefore prior to commencing the Trial an advertisement was 
posted on the Macmillan’s Cancer Support online community noticeboard 
(http://community.macmillan.org.uk/volunteering/noticeboard/default.aspx) and also 
6 
 
on Beating Bowel Cancer’s patient forum 
(http://www.beatingbowelcancer.org/forum), asking bowel cancer patients for their 
general opinions and thoughts on the Trial. The feedback received was positive. The 
study was considered to be “worthwhile”. 
 
3. Methods  
 
In accordance with the Protocol, a longitudinal cohort study was implemented 
between 1 April 2014 and 1 December 2014 inclusive (the ‘Trial Period’). Data was 
collected at:   ‘T1” post-surgery and prior to chemotherapy treatment  ‘T2” twelve to fourteen weeks after first scheduled chemotherapy treatment 
or 3 months post surgery (as appropriate)  ‘T3” three months after last scheduled chemotherapy treatment or 
approximately 6 months after T2 (as appropriate). 
 
3.1 Participants 
During the Trial Period, a consecutive sample of patients between the ages of 18 
and 65, diagnosed with resectable CRC under the care of the CRC team were 
invited to participate.  
Eligibility required patients to:    
a) Have undergone colorectal surgery 
b) Not have distant metastases; and 
c) Require adjuvant chemotherapy treatment or no post-surgery treatment at all. 
 
Patients with prior exposure to chemotherapy and those with significant psychiatric 
or medical comorbidities, which might affect ability to participate in the Trail, were 
excluded. Patients could not enter the Trial if they were unable to read and speak 
English. 
3.2 Measures 
The measures used are detailed in the Protocol (Dwek et al, 2015). 
  
3.3 Trial sample size  
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Extrapolating from the Protocol’s power calculation and assuming a total sample size 
of 156 participants (78 per group) to be recruited over 18 months, an average of 
eight to ten patients per calendar month would need to be consented into the Trial. 
 
3.4 Procedure 
Potential participants were identified at the weekly CRC multi-disciplinary team 
(MDT) meetings held by each Trust.  
 
Proposed recruitment procedures were as follows:   At the participant’s post-surgery follow-up appointment, typically three to six 
weeks after surgery (‘OPA’), a member of the clinical team would introduce 
the researcher to the patient.   The researcher would then provide the patient with written information about 
the Trial and answer questions raised.   The patient would be asked if they would be willing to be contacted by 
telephone within a few days to discuss participation in the Trial. Patients who 
agreed to participate were then given an appointment to meet with the 
researcher either at the hospital or at home.  
 
Those patients who did not wish to participate after reviewing the information sheets 
were not contacted again.  
 
T1 assessments were planned to take place one to two weeks after the OPA and 
prior to the patient’s first scheduled chemotherapy appointment or at a parallel point 
in time for the surgery-only group. Eligible participants were to be consented into the 
Trial immediately prior to T1. The assessments for T1 were expected to take each 
participant approximately 2 hours and 30 minutes to complete. 
At the end of T1 participants were advised that they would be contacted again via 
telephone within approximately 10 to 12 weeks to arrange the meeting for T2. T2 
would be scheduled for between 12 and 14 weeks after T1 or between cycle 6 and 
cycle 7 in the case of the chemotherapy treatment group and at a parallel point in 
time for the surgery only group. 
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The same process would be utilised for T3, with assessments carried out at 
participants’ homes at approximately 3 months after the final scheduled 
chemotherapy treatment, and at a similar point in time for the surgery-only 
participants.  
 
Based on the sample size calculation set out in the Protocol, the attrition rate could 
not exceed 22%. 
 
4. Results 
  
4.1 Recruitment procedures 
The Trial indicated that procedures were quite similar at each Trust.  At all Trusts the 
surgery-only follow-up appointments were more difficult to determine than the 
chemotherapy patients.  
 
4.2  Participant numbers 
Recruiting from three Trusts (six hospital sites), attending all MDT's, surgical and 
chemotherapy clinics whilst also carrying out all assessments exceeded the single 
researcher’s capacity; indicating that recruitment would require additional staff.  
 
The surgery only control group proved more complex to recruit, as there were 
multiple surgeons at each hospital site making it difficult to identify all follow up 
OPAs. In addition eligible surgery-only participants approached by the researcher 
often refused participation as they asserted that they had completed treatment.  
Forty-two CRC patients across 3 Trusts were invited to participate during the Trial 
Period, twenty-three agreed and were consented, however six changed their minds 
prior to completing T1. At the end of the Trial Period seventeen had completed T1 
and eight T2. Sixteen of the seventeen remained in the Trial after the Trial Period 
and completed T2. One patient withdrew after T1 due to the appearance of a new 
cancer lesion. The sample at T1 was made up from 35% males and 65% females 
with a mean age of 58.7 years. 
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Thirteen of the seventeen participants (76 %) were in the chemotherapy group. 
However, one participant was advised to start chemotherapy treatment several 
weeks after completing T1 and another that started in the chemotherapy group 
stopped treatment after three cycles but continued in the Trial.  
 
The rate of recruitment was approximately three per month once the recruitment 
procedures and working practices were established. This indicated that significantly 
more research capacity and sites were required as it would take approximately four 
years to recruit the 156 participants required with the current resource.   
 
Inclusion/exclusion criteria 
Eligible participants were lower in number than expected in part due to the 
inclusion/exclusion criteria, age and also competing trials. Following ethics approval 
the age criterion was altered to have no upper age limit to increase recruitment.  
 
4.3 Methodology/Testing of data collection procedures and assessments 
All participants completed the full Battery.  Consequently the administration of the 
Battery was deemed appropriate. 
 
A suitable testing environment was achieved by administering the Battery in a quiet 
space both at the hospitals and participants’ homes.  
 
At the completion of T1, participants were asked how they felt about the 
assessments.  The comments made suggested that participants in both groups 
found the design, methods and procedures employed in the Trial appropriate.  
 
ID 1: “this was very enjoyable” 
ID 14: “It took my mind off things, I enjoyed doing it” 
 
4.4 Attrition rates  
During the Trial Period, attrition at T2 was very low with only 1 participant 
withdrawing due to ill health. All participants who completed T1 expressed a desire 
to continue in the Trial. Continued participation in the Trial would suggest that the 
proposed multi-site study is worthwhile. 
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Conclusions  
 
The Trial provided evidence that the Protocol is feasible subject to increasing the 
number of researchers and collaborating sites both to improve recruitment rates and 
to prevent clashes with assessments.  
 
One possible solution to improving the rate of recruitment was implemented during 
the Trial Period, by removing the upper age limit for eligible participants. This has 
since made a difference in number of consented participants. 
 
The number of patients consenting to the Trial and a very low attrition rate suggests 
that many CRC patients are willing to participate and that the Battery is feasible and 
well tolerated by patients.  
 
Another strength of the proposed Protocol evidenced during the Trial was the 
acceptability of the multi-site study to clinical teams demonstrated by requests of 
collaboration from two additional London based NHS Trusts. In addition, the Trial 
provides valuable information to other neuropsychologists interested in the cognitive 
effect of chemotherapy treatments in the form of a realistic plan. It also makes clear 
the requirement for sufficient funding and resources. This could in turn allow for a 
large multi-institutional study across several English speaking cities and/or countries. 
All institutions could administer the same neuropsychological battery to a very large 
number of solid tumour cancer patients and pool all data as suggested by the 
International Cancer and Cognition Task Force (Wefel, Lenzi, Theriault, Davis and 
Meyers, 2011). 
One potential limitation of the proposed study however, is that the majority of 
patients had never heard of chemotherapy related cognitive changes, which may 
cause concern and/or priming effects. However, in the event that priming does occur 
it will do so in both the chemotherapy group and the surgery only group, so useful 
comparisons between the groups of any observed objective changes may still be 
made. In addition, any possible priming effects will not prohibit the researchers from 
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being able to examine the impact of chemotherapy related subjective cognitive 
changes on the individuals’ quality of life. 
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